PARKINSON'S DISEASE RISK FACTORS. REVIEW
Introduction. Parkinson's disease (PD), in recent decades, remains a pressing problem in the modern world. The disease refers to the pathology of the extrapyramidal system, where the deep parts of the brain, the so-called basal ganglia, are affected. During a medical examination, at first glance, movement disorders are striking, and the patient himself or his relatives make complaints related to movement disorders. However, the disease, by the time the complaints were made, takes its beginning 5-10 years ago with non-motor manifestations, such as sleep disturbances, apathy, increased fatigue, and constipation. According to genetic studies, 10 to 15% of cases are caused by mutations in genes. The etiology of the disease is still unclear, but it is considered a consequence of the associated effects of genetic and environmental factors.
Aim: This review evaluates relevant information on the risk factors for Parkinson's disease.
Search Strategy. A literature review was conducted with the help of bibliographic databases Pubmed, Web of Science, and Scopus with the search keywords: Parkinson's disease, epidemiology, etiology, risk factors, gender, age. The depth of the search covered 10 years, from 2011 to 2021. Forty-three articles have been selected as analytical material and have undergone a critical evaluation process. In several cases, there is a reference to an earlier publication with historical and scientific value. The literature search included only English-language publications.
Results and Conclusions. In summary, after analyzing 43 articles, it was concluded that PD is a complex neurodegenerative disease resulting from the interaction of genetic and external factors, which, as a consequence, affect numerous fundamental cellular processes of the body. Therefore, environmental influences can contribute to the development of PD, which emphasizes the importance of identifying risk factors for the disease. Understanding the mechanisms of pathogenesis will enable the identification of new therapeutic targets, which will subsequently help in the development of new combined, possibly individualized treatments.
Saltanat O. Abdraimova1, https://orcid.org/0000-0003-0162-2330
Nazira A. Zharkinbekova1, https://orcid.org/0000-0002-5069-1562
1 South Kazakhstan Medical Academy, Department of Neurology, Psychiatry, Rehabilitation and Neurosurgery, Shymkent, Republic of Kazakhstan.
1. Аbbott R.D., Ross G.W., Petrovitch H., et al. Midlife milk consumption and substantia nigra neuron density at death. Neurology 2016. 86:512–519
2. Airavaara M., Parkkinen I., Konovalova J., Albert K., Chmielarz P., Domanskyi A. Back and to the future: From neurotoxin-induced to human parkinson’s disease models. Current Protocols in Neuroscience. 2020. 91. e88. doi:10.1002/cpns.88
3. Ascherio A., Schwarzschild M.A. The epidemiology of Parkinson's disease: risk factors and prevention. The Lancet Neurology. 2016. 15. 12. 1257-1272.
4. Aviles-Olmos I., Limousin P., Lees A., Foltynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain. 2013. 136, 374–384. doi:10.1093/brain/aws009.
5. Beitz J.M., Parkinson s disease a review. Frontiers in Bioscience-Scholar S6, 2014. 65–74. doi:10.2741/s415
6. Cagac A., Farming, well water consumption, rural living, and pesticide exposure in early life as the risk factors for Parkinson disease in Iğdır province. Neurosciences 2020. 25, 129–135. doi:10.17712/nsj.2020.2.20190104.
7. Cerri S., Mus L., Blandini F. Parkinson's Disease in Women and Men: What's the Difference? J Parkinsons Dis. 2019. 9(3):501-515. doi: 10.3233/JPD-191683. PMID: 31282427. PMCID: PMC6700650.
8. Chen H., O’Reilly E., McCullough M.L., et al. Consumption of dairy products and risk of Parkinson’s disease. Am J Epidemiol 2007. 165:998–1006.
9. Chen J.-F., Schwarzschild M.A. Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease? Parkinsonism & Related Disorders 2020. 80, S45–S53. doi:10.1016/j.parkreldis.2020.10.024
10. Colombo D., Abbruzzese G., Antonini A., Barone P., Bellia G., Franconi F., Simoni L., Attar M., Zagni E., Haggiag S., Stocchi F. The "gender factor" in wearing-off among patients with Parkinson's disease: a post hoc analysis of DEEP study. Scientific World Journal. 2015. 2015:787451. doi: 10.1155/2015/787451. Epub 2015 Jan 20. PMID: 25685848. PMCID: PMC4320843
11. Dahodwala N., Shah K., He Y., Wu S.S., Schmidt P., Cubillos F., Willis A.W. Sex disparities in access to caregiving in Parkinson disease. Neurology 2018. 90, 48-e54.
12. Elbaz A., Carcaillon L., Kab S., Moisan F. Epidemiology of Parkinson's disease. Rev Neurol (Paris). 2016 Jan. 172(1):14-26. doi: 10.1016/j.neurol.2015.09.012. Epub 2015 Dec 21. PMID: 26718594.
13. Gao X., O’Reilly E.J., Schwarzschild M.A., Ascherio A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology 2016. 86:520–526.
14. Hirsch L., Jette N., Frolkis A., Steeves T., Pringsheim T. The incidence of Parkinson’s disease: A systematic review and meta-analysis. Neuroepidemiology, 2016.46, 292-300.
15. Hong C.T., Chan L., Bai C.-H. The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis. Nutrients 2020. 12, 1860.. doi:10.3390/nu12061860
16. Hughes K.C., Gao X., Kim I.Y., Wang M., Weisskopf M.G., Schwarzschild M.A., Ascherio A. Intake of dairy foods and risk of Parkinson's disease. Neurology. 2017 Jul 4. 89(1):46-52. doi: 10.1212/WNL.0000000000004057. Epub 2017 Jun 8. PMID: 28596209, PMCID: PMC5496517.
17. Kasdagli M.I., Katsouyanni K., Dimakopoulou K., Samoli E. Air pollution and Parkinson's disease: A systematic review and meta-analysis up to 2018. Int J Hyg Environ Health. 2019 Apr. 222(3):402-409. doi: 10.1016/j.ijheh.2018.12.006. Epub 2018 Dec 31. PMID: 30606679.
18. Kasten M., Chade A., Tanner C.M. Epidemiology of Parkinson's disease. Handb Clin Neurol. 2007. 83:129-51. doi: 10.1016/S0072-9752(07)83006-5. PMID: 18808913. PMCID: PMC7112363.
19. Kyrozis A., Ghika A., Stathopoulos P., Vassilopoulos D., Trichopoulos D., Trichopoulou A. Dietary and lifestyle variables in relation to incidence of Parkinson’s disease in Greece. Eur J Epidemiol. 2013. 28:67–77.
20. Lee A., Gilbert R.M. Epidemiology of Parkinson Disease. Neurol Clin. 2016 Nov. 34(4):955-965. doi: 10.1016/j.ncl.2016.06.012. Epub 2016 Aug 18. PMID: 27720003.
21. Lin S.S., Kelsey J.L. Use of race and ethnicity in epidemiologic research: concepts, methodological issues, and suggestions for research. Epidemiol Rev. 2000. 22:187–202
22. Moccia M., Erro R., Picillo M., Vitale C., Longo K., Amboni M., Pellecchia M.T., Barone P. Caffeine consumption and the 4-year progression of de novo Parkinson's disease. Parkinsonism & related disorders. 2016 Nov 1. 32:116-9.
23. Müller J., Myers J. Association between physical fitness, cardiovascular risk factors, and Parkinson's disease // Eur J Prev Cardiol. 2018 Sep. 25(13):1409-1415. doi: 10.1177/2047487318771168. Epub 2018 Apr 18. PMID: 29667433.
24. Ou R., Liu H., Hou Y., Song W., Cao B., Wei Q., Yuan X., Chen Y., Zhao B., Shang H. Predictors of camptocormia in patients with Parkinson’s disease: A prospective study from southwest China. Parkinsonism Relat Disord 2018. 52, 69-75
25. Pagano G., Polychronis S., Wilson H., Giordano B., Ferrara N., Niccolini F., Politis M. Diabetes mellitus and Parkinson disease. Neurology. 2018 May 8. 90(19):e1654-e1662. doi: 10.1212/WNL.0000000000005475. Epub 2018 Apr 6. PMID: 29626177.
26. Pringsheim T., Jette N., Frolkis A., Steeves T.D. The prevalence of Parkinson's disease: a systematic review and meta‐analysis // Movement disorders. 2014 Nov. 29(13):1583-90.
27. Reich S.G., Savitt J.M. Parkinson's Disease. Med Clin North Am. 2019 Mar. 103(2):337-350. doi: 10.1016/j.mcna.2018.10.014. Epub 2018 Dec 3. PMID: 30704685.
28. Saaksjarvi K., Knekt P., Lundqvist A., et al. A cohort study on diet and the risk of Parkinson’s disease: the role of food groups and diet quality. Br J Nutr 2013. 109: 329–337.
29. Saaksjarvi K., Knekt P., Mannisto S., et al. Reduced risk of Parkinson’s disease associated with lower body mass index and heavy leisure-time physical activity. Eur J Epidemiol. 2014. 29: 285–292.
30. Savica R., Grossardt B.R., Rocca W.A., Bower J.H. Parkinson disease with and without dementia: A prevalence study and future projections. Mov Disord. 2018. 33, 537-543.
31. Searles Nielsen S., Gallagher L.G., Lundin J.I. et al. Environmental tobacco smoke and Parkinson’s disease. Mov Disord 2012. 27: 293–296.
32. Shih I.F., Liew Z., Krause N., et al. Lifetime occupational and leisure time physical activity and risk of Parkinson’s disease // Parkinsonism Relat Disord. 2016. 28: 112–117
33. Sieurin J., Zhan Y., Pedersen N.L., Wirdefeldt K. Neuroticism, Smoking, and the Risk of Parkinson's Disease. J Parkinsons Dis. 2021. 11(3):1325-1334. doi:10.3233/JPD-202522. PMID: 34024779, PMCID: PMC8461727.
34. Simon D.K., Wu C., Tilley B.C., Wills A.-M., Aminoff M.J., Bainbridge J., Hauser R.A., Schneider J.S., Sharma S., Singer C., Tanner C.M., Truong D., Wong P.S. Caffeine and Progression of Parkinson Disease. Clinical Neuropharmacology 2015. 38, 163–169. doi:10.1097/wnf.0000000000000102
35. Solla P., Cannas A., Ibba F.C., Loi F., Corona M., Orofino G., Marrosu M.G., Marrosu F. Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson’s disease. J Neurol Sci. 2012. 323, 33-39.
36. Tanner C.M., Kamel F., Ross G.W. et al. Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect. 2011. 119: 866–72.
37. Tolosa E., Garrido A., Scholz S.W., Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021 May. 20(5):385-397. doi: 10.1016/S1474-4422(21)00030-2. PMID: 33894193, PMCID: PMC8185633.
38. Tysnes O.-B., Storstein A., Epidemiology of Parkinson’s disease. Journal of Neural Transmission 2017. 124, 901–905. doi:10.1007/s00702-017-1686-y
39. von Campenhausen S., Bornschein B., Wick R., et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol. 2005. 15: 473–490.
40. Wirdefeldt K., Adami H.-O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. European Journal of Epidemiology 2011. 26, 1–58. doi:10.1007/s10654-011-9581-6.
41. Wong S.L., Gilmour H., Ramage-Morin P.L. Parkinson's disease: Prevalence, diagnosis and impact. Health Rep. 2014 Nov. 25(11):10-4. PMID: 25408491.
42. Yang F., Trolle Lagerros Y., Bellocco R., et al. Physical activity and risk of Parkinson’s disease in the Swedish National March Cohort. Brain. 2015. 138: 269–275.
43. Yue X., Li H., Yan H., Zhang P., Chang L., Li T. Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies. Medicine 2016. 95: e3549.
Количество просмотров: 435
Категория статей:
Обзор литературы
Библиографическая ссылка
Abdraimova S.O., Zharkinbekova N.A. Parkinson's disease risk factors. Review // Nauka i Zdravookhranenie [Science & Healthcare]. 2022, (Vol.24) 6, pp. 245-250. doi 10.34689/SH.2022.24.6.029Похожие публикации:
UNDERSTANDING OF RECURRENT RESPIRATORY INFECTIONS IN CHILDREN AT THE PRESENT STAGE. REVIEW.
ГЕМОДИНАМИЧЕСКИ ЗНАЧИМЫЙ ОТКРЫТЫЙ АРТЕРИАЛЬНЫЙ ПРОТОК У НЕДОНОШЕННЫХ НОВОРОЖДЕННЫХ ДЕТЕЙ. ОБЗОР ЛИТЕРАТУРЫ
RADIOIODINE-RESISTANT DIFFERENTIATED THYROID CANCER: CLINICOPATHOLOGICAL CHARACTERISTICS, MOLECULAR GENETIC ALTERATIONS. REVIEW.
ПРЕРЫВИСТАЯ КАТЕТЕРИЗАЦИЯ МОЧЕВОГО ПУЗЫРЯ КАК «ЗОЛОТОЙ СТАНДАРТ» ЛЕЧЕНИЯ НЕЙРОГЕННОГО МОЧЕВОГО ПУЗЫРЯ У ЛИЦ, С ПОВРЕЖДЕНИЕМ СПИННОГО МОЗГА
АНАЛИЗ ОПЫТА МЕДСЕСТЕР И ФАКТОРОВ, ВЛИЯЮЩИХ НА ДОБРОВОЛЬНОЕ СООБЩЕНИЕ ОБ ИНЦИДЕНТАХ